JP2023508182A - トリアゾロトリアジン誘導体の疾患治療への応用 - Google Patents

トリアゾロトリアジン誘導体の疾患治療への応用 Download PDF

Info

Publication number
JP2023508182A
JP2023508182A JP2022539212A JP2022539212A JP2023508182A JP 2023508182 A JP2023508182 A JP 2023508182A JP 2022539212 A JP2022539212 A JP 2022539212A JP 2022539212 A JP2022539212 A JP 2022539212A JP 2023508182 A JP2023508182 A JP 2023508182A
Authority
JP
Japan
Prior art keywords
group
furan
triazolo
triazine
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508182A5 (enExample
Inventor
サンシン スン
ゼンシュ チェン
ジンチー イエ
ロン ジャオ
チョンボ フー
ヨン ヤン
フェン グァン
シューファ パン
ニン フー
ティンティン パン
グオウェイ ソン
ファンジェ ホウ
Original Assignee
チェジン ヴィムグリーン ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チェジン ヴィムグリーン ファーマシューティカルズ リミテッド filed Critical チェジン ヴィムグリーン ファーマシューティカルズ リミテッド
Publication of JP2023508182A publication Critical patent/JP2023508182A/ja
Publication of JP2023508182A5 publication Critical patent/JP2023508182A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022539212A 2019-12-26 2020-12-25 トリアゾロトリアジン誘導体の疾患治療への応用 Pending JP2023508182A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911364028.2 2019-12-26
CN201911364028 2019-12-26
PCT/CN2020/139690 WO2021129843A1 (zh) 2019-12-26 2020-12-25 三唑并三嗪衍生物在治疗疾病中的用途

Publications (2)

Publication Number Publication Date
JP2023508182A true JP2023508182A (ja) 2023-03-01
JP2023508182A5 JP2023508182A5 (enExample) 2024-01-04

Family

ID=76573699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539212A Pending JP2023508182A (ja) 2019-12-26 2020-12-25 トリアゾロトリアジン誘導体の疾患治療への応用

Country Status (5)

Country Link
US (1) US20230048888A1 (enExample)
EP (1) EP4083044A4 (enExample)
JP (1) JP2023508182A (enExample)
CN (1) CN114901665B (enExample)
WO (1) WO2021129843A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597855A (ja) * 1990-05-29 1993-04-20 Imperial Chem Ind Plc <Ici> アゾール誘導体
JPH05222045A (ja) * 1991-11-25 1993-08-31 Imperial Chem Ind Plc <Ici> アゾール誘導体
JP2005511697A (ja) * 2001-11-30 2005-04-28 シェーリング　コーポレイション ［１，２，４］−トリアゾール二環式アデノシンＡ２ａレセプタアンタゴニスト
JP7197206B2 (ja) * 2018-06-26 2022-12-27 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド Ａ２ａ受容体拮抗薬として用いられるトリアゾロトリアジン誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356894A (en) * 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
CA2148502A1 (en) * 1993-09-06 1995-03-16 Fumio Suzuki Antidepressants
JP4228048B2 (ja) 2000-10-09 2009-02-25 ピーオーダブリューエムアールアイ リミテッド 神経変性障害の検出方法
DE60231386D1 (de) * 2001-04-09 2009-04-16 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
WO2004092173A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2018013951A1 (en) * 2016-07-15 2018-01-18 Northwestern University Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
TWI801372B (zh) * 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
KR102633145B1 (ko) * 2018-06-26 2024-02-05 쩌지앙 빔그린 파머슈티컬스, 엘티디 A2a 수용체 길항제로서의 트리아졸로 트리아진 유도체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597855A (ja) * 1990-05-29 1993-04-20 Imperial Chem Ind Plc <Ici> アゾール誘導体
JPH05222045A (ja) * 1991-11-25 1993-08-31 Imperial Chem Ind Plc <Ici> アゾール誘導体
JP2005511697A (ja) * 2001-11-30 2005-04-28 シェーリング　コーポレイション ［１，２，４］−トリアゾール二環式アデノシンＡ２ａレセプタアンタゴニスト
JP7197206B2 (ja) * 2018-06-26 2022-12-27 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド Ａ２ａ受容体拮抗薬として用いられるトリアゾロトリアジン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JORG, M. ET AL.: ""Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of s", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 11, JPN6022015800, 2013, pages 3427 - 3433, XP028535132, ISSN: 0005603436, DOI: 10.1016/j.bmcl.2013.03.070 *
SIHVER, W. ET AL.: ""Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors"", NUCLEAR MEDICINE AND BIOLOGY, vol. 31, no. 2, JPN6022015796, 2004, pages 173 - 177, ISSN: 0005603435 *

Also Published As

Publication number Publication date
EP4083044A4 (en) 2024-03-27
CN114901665B (zh) 2025-02-18
US20230048888A1 (en) 2023-02-16
CN114901665A (zh) 2022-08-12
EP4083044A1 (en) 2022-11-02
WO2021129843A1 (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
JP6980649B2 (ja) イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
JP6736559B2 (ja) トリアゾロピリミジン化合物およびその使用
US10316032B2 (en) Solid forms of a compound for modulating kinases
JP6838085B2 (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
JP6883049B2 (ja) アミノチアゾール化合物及びその使用
EP3472161B1 (en) Triazolopyridine compounds and uses thereof
CN113620958A (zh) 用于治疗PI3K-γ介导的障碍的杂环化合物
TW201339155A (zh) □唑啶－２－酮化合物及其用途
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
JP2017214387A (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
JP5681226B2 (ja) メチルフェニデート誘導体を含む治療剤
CA3067695A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
Wang et al. New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities
JP2024526305A (ja) Ｌｒｒｋ２の野生型および変異体形態の分解剤ならびにその使用
US20210246120A1 (en) Method of preparation and use of phosphoinositide 3-kinase inhibitors in treating cancer
JP2024511466A (ja) Ａｌｋ－５阻害剤及びその使用
CA3173679A1 (en) Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1) and uses thereof
JP2015534990A (ja) 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
JP2020045339A (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
JP2023508182A (ja) トリアゾロトリアジン誘導体の疾患治療への応用
CN120676939A (zh) Pi3k抑制剂及其制备和使用方法
WO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
TWI920088B (zh) Ｓｉｋ-３抑制劑及其用途
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
JP2026507092A (ja) 健康状態の治療のための小分子を作製および使用するための組成物および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527